ClinicalTrials.gg
TerminatedNCT01079364BASAAL PLUSUpdated May 29, 2013

Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting

A Phase 4 interventional study of Insulin glulisine and Insulin glargine in Diabetes Mellitus, Type 2, sponsored by Sanofi. Terminated at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-29.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Why this study was terminated
Slow recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 2.

Enrollment
20th of 25
52 · median 281
Started
2010
with 2 others
Phase 4
14 of 26
none open now
Registered
17th of 26
by date
Lead sponsor
19 of 26
Sanofi

Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2, this one is the 20th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2010, is one of 14 in phase 4, and was the 17th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

Primary Objective:

To demonstrate non-inferiority of once daily injection of insulin glargine (Lantus) plus one injection of mealtime insulin glulisine (Apidra) at the main meal versus twice daily premixed insulin (NovoMix 30/70) based on the reduction of HbA1c percentage from baseline to endpoint.

Secondary Objective:

  • To determine treatment satisfaction (DTSQs/Diabetes Treatment Questionnaire - Status, DTSQc/ Diabetes Treatment Questionnaire - change and ITSQ/Insulin Treatment Satisfaction Questionnaire)
  • To determine the mean HbA1c, FBG (Fasting Blood Glucose), prandial BG (Blood Glucose) and proportion of patients with a HbA1c \<7%
  • To determine the effect on adverse events (e.g. symptomatic hypoglycemic events, weight gain and injection site reactions)
  • To determine the total insulin dose, average insulin glargine, insulin glulisine and premixed insulin dosages.
03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 2 diabetes mellitus treated with insulin glargine once daily and oral blood glucose lowering medication
  • Patients with a > 7%
  • Patients with a FBG within range (4-7 mmol/L) at baseline, based on the mean of 3 FBG values (measured 5x during the run-in phase, with the highest and lowest value excluded)

Exclusion criteria

Exclusion criteria:

  • Patients treated with an insulin other than insulin glargine
  • Patients with to insulin glargine, insulin glulisine, biphasic insulin aspart/insulin aspart protamine 30/70 or any of the
  • Patients with a (pre)proliferative retinopathy (an optic fundus examination should have been performed within the 2 years prior to study entry)
  • Pregnant or lactating women
  • Patients who are unable to fill in the PRO (Patient Reported Outcomes) questionnaires

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Insulin glargine + Insulin glulisine

    Daily injection of insulin glargine plus one injection of mealtime insulin glulisine at the main meal

    Drug: Insulin glulisine · Drug: Insulin glargine

  • Active comparator
    Premixed insulin

    twice daily premixed insulin (before breakfast and evening meal).

    Drug: Premixed insulin (Insulin Aspart 30/70 )

Interventions

  • Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day

    Also known as: Apidra®

  • Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day

    Also known as: Lantus®

  • DrugPremixed insulin (Insulin Aspart 30/70 )

    Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily

    Also known as: NovoMix 30/70®

06

What researchers measure

Primary outcomes

  1. Glycosylated Haemoglobin (HbA1c) Value

    Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients.

    Time frame: at screening (week - 2), week 12 (if available) and 24

  2. Self Measured Blood Glucose (SMBG)

    Time frame: at Baseline (week 0), week 2, 12 and 24

Secondary outcomes

  1. DTSQs (Diabetes Treatment Satisfaction Questionnaire - status)

    Time frame: at week 0, 12 and 24

  2. DTSQc (Diabetes Treatment Satisfaction Questionnaire - change)

    Time frame: at week 24

  3. ITSQ (Insulin Treatment Satisfaction Questionnaire)

    Time frame: at week 0, 12 and 24

  4. Hypoglycemic events

    Time frame: at week 0, 2, 12 and 24

  5. Adverse Events (excluding hypoglycemic events)

    Time frame: at week - 2, 0, 2, 12 and 24

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2010
First posted
Mar 3, 2010
Start
Jan 2010
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Last update
May 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01079364
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 3, 2010
Start date
Jan 2010
Primary completion
Jul 2012
Completion
Jul 2012
Last update
May 29, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin glulisine · Insulin Glargine

Start the discussion